https://www.epmtherapeutics.com/faq 1.0 monthly 2026-03-16 https://www.epmtherapeutics.com/about 1.0 monthly 2026-02-15 https://www.epmtherapeutics.com/prader-willi-syndrome 1.0 monthly 2026-03-16 https://www.epmtherapeutics.com/contact 1.0 monthly 2026-01-06 https://www.epmtherapeutics.com 1.0 monthly 2026-03-16 https://www.epmtherapeutics.com/future-developments 1.0 monthly 2026-01-13 https://www.epmtherapeutics.com/epm301 1.0 monthly 2026-03-16 https://www.epmtherapeutics.com/our-team 1.0 monthly 2026-03-16 https://www.epmtherapeutics.com/investors 1.0 monthly 2026-01-10 https://www.epmtherapeutics.com/news-and-presentation 1.0 monthly 2025-12-29 https://www.epmtherapeutics.com/blog/epm-therapeutics-announces-successful-pre-ind-meeting-with-fda-for-epm301 0.8 monthly 2026-03-09 https://www.epmtherapeutics.com/epm-therapeutics-secures-fda-pre-ind-meeting-to-advance-epm301-for-prader-willi-syndrome 0.8 monthly 2026-01-10 https://www.epmtherapeutics.com/comprehensive-therapeutic-potential-of-epm301-for-hyperphagia-anxiety-and-sleep-disturbances-in-prader-willi-syndrome 0.8 monthly 2025-12-08 https://www.epmtherapeutics.com/preclinical-findings-suggest-that-epm301-could-offer-multiple-benefits-as-a-novel-treatment-for-symptoms-of-prader-willi-syndrome 0.8 monthly 2025-12-08 https://www.epmtherapeutics.com/enhanced-bioavailability-and-therapeutic-potential-of-epm301-a-novel-cannabidiol-analogue-in-the-treatment-of-prader-willi-syndrome 0.8 monthly 2025-12-29